16 September 2026 editorial review · Item
Insulin efsitora alfa (basal Fc): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Insulin efsitora alfa (basal Fc)
Scope and findings:
- EMA Onswik remains positiveCHMPopinion25 June 2026,adultT2only;NICE T1 projectdiscontinued30 July 2026. NoECdecision posted on retrievedEPAR. RegistryQWINT5 completed 692. No newT1approval established.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.